Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Lamivudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 8
States / cities: San Francisco, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 5 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Islatravir (ISL), Lamivudine (3TC); Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: HIV Infections
Interventions: ARV regimen chosen by treating physician; Drug
Lead sponsor: Kristine Patterson, MD; Other
Eligibility: 19 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections, Hepatitis C
Interventions: Efavirenz, Lamivudine, Lopinavir/ritonavir, Pegylated interferon alfa-2a, Ribavirin, Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: dolutegravir 50 mg OAD, darunavir 800mg OAD, ritonavir 100mg OAD; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 33
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 25 more

Conditions: HIV Infections
Interventions: FDA Approved Antiretroviral Therapy (see list below); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 5
States / cities: San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more

Conditions: HIV Infection
Interventions: abacavir/lamivudine/zidovudine, tenofovir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 27
States / cities: Los Angeles, California • San Rafael, California • Fort Lauderdale, Florida + 22 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA), Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 45
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 28 more

Conditions: Hepatitis B
Interventions: telbivudine, adefovir dipivoxil; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 2
States / cities: San Diego, California • San Mateo, California

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate; Drug · Biological
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Volunteers
Interventions: Abacavir/Lamivudine, Lersivirine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections
Interventions: Efavirenz, Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 46
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: HIV Infections, Human Immunodeficiency Virus
Interventions: Dexelvucitabine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 10
States / cities: Long Beach, California • Brandon, Florida • Fort Lauderdale, Florida + 7 more

Conditions: AIDS Dementia Complex, HIV Infections
Interventions: CPI-1189; Drug
Lead sponsor: Centaur Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Extensive Stage Lung Small Cell Carcinoma
Interventions: Atezolizumab, Carboplatin, Etoposide, Lamivudine; Biological · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Chronic Hepatitis B
Interventions: ACH126, 433; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 13
States / cities: Los Angeles, California • Orange, California • Pasadena, California + 8 more

Conditions: HIV-1-infection
Interventions: Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 38
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 14 more

Conditions: HIV Infections, Pregnancy
Interventions: Lamivudine, Lamivudine/Zidovudine, Nelfinavir mesylate, Nevirapine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years and older · Female only
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 44
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 28 more

Conditions: HIV Infections
Interventions: Delavirdine mesylate, Lamivudine, Zidovudine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 14 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 87
States / cities: Birmingham, Alabama • Berkeley, California • Clovis, California + 63 more

Conditions: Medication Adherence, HIV
Interventions: dolutegravir oral tablet 50mg, emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg, tenofovir disoproxil fumarate oral tablet 300mg, lamivudine oral tablet 300mg; Drug
Lead sponsor: Rhonda Brand; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 12 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • Sherman Oaks, California + 15 more

Search by objective public record fields.

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

Evaluation of the Bioequivalence of a Combined Formulated Tablet

A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)

Sex, Aging and Antiretroviral Pharmacokinetics

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

Clinical Trial of CNS-targeted HAART (CIT2)

Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients

Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects

Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC

Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs

Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B

Study of Novel Antiretrovirals in Participants With HIV-1

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past